|
|
|
Insider
Information: |
Boyd Steven |
Relationship: |
10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
47,075,098 |
|
Indirect Shares
|
40,287,245 |
|
|
Direct
Value |
$124,670,210 |
|
|
Indirect Value
|
$39,932,089 |
|
|
Total
Shares |
87,362,343 |
|
|
Total
Value |
$164,602,299 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
99
|
96
|
Stock
price went up :
|
54
|
46
|
Stock
price went down : |
45
|
50
|
|
|
|
Gain/Loss Ratio : |
1.2
|
1.2
|
Percentage
Gain/Loss : |
-16.7%
|
8,928.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Avalo Therapeutics, Inc |
AVTX |
10% Owner |
2023-06-27 |
34,370 |
2023-06-27 |
731,458 |
Premium* |
|
Dynatronics Corp |
DYNT |
10% Owner |
2017-03-21 |
500,000 |
2017-03-21 |
1,000,000 |
Premium* |
|
Kiora Pharmaceuticals |
KPRX |
10% Owner |
2021-01-06 |
3,346,601 |
2021-08-02 |
785,000 |
Premium* |
|
Fresh Tracks Therapeutics Ord Shs |
FRTX |
10% Owner |
2019-01-10 |
2,170,000 |
2019-01-10 |
2,170,000 |
Premium* |
|
Alimera Sciences Inc |
ALIM |
10% Owner |
2018-02-06 |
6,936,000 |
2018-02-06 |
6,936,000 |
Premium* |
|
Cassava Sciences Inc |
SAVA |
10% Owner |
2018-10-03 |
1,651,340 |
2018-10-03 |
0 |
Premium* |
|
Del Friscos Restaurant Group, Llc |
DFRG |
10% Owner |
2019-09-25 |
0 |
2019-09-25 |
0 |
Premium* |
|
Valeritas Holdings Inc |
VLRX |
10% Owner |
2019-12-20 |
0 |
2019-12-20 |
0 |
Premium* |
|
Bio-Path Holdings, Inc. |
BPTH |
10% Owner |
2019-01-18 |
129,298 |
2019-01-18 |
129,298 |
Premium* |
|
AYTU BIOSCIENCE, INC |
AYTU |
Director |
2021-03-29 |
1,342,378 |
2021-03-29 |
1,342,378 |
Premium* |
|
Achieve Life Sciences Inc |
ACHV |
10% Owner |
2019-06-11 |
843,776 |
2019-06-11 |
843,776 |
Premium* |
|
AMAG Pharmaceuticals Inc |
AMAG |
10% Owner |
2020-03-16 |
4,120,000 |
2020-03-16 |
348,000 |
Premium* |
|
Onconova Therapeutics, Inc. |
ONTX |
10% Owner |
2019-09-23 |
816,702 |
2019-09-23 |
816,702 |
Premium* |
|
Vaxart Inc |
VXRT |
Director |
2020-06-29 |
145,523 |
2020-06-29 |
145,523 |
Premium* |
|
Tetraphase Pharmaceuticals Inc |
TTPH |
Director, 10% Owner |
2020-07-28 |
0 |
2020-07-28 |
0 |
Premium* |
|
Tenax Therapeutics Inc |
TENX |
Director, 10% Owner |
2020-09-08 |
2,019,995 |
2020-09-08 |
2,019,995 |
Premium* |
|
Cyclo Therapeutics, Inc |
CYTH |
10% Owner |
2020-09-30 |
15,795,769 |
2020-09-30 |
15,795,769 |
Premium* |
|
ReShape Lifesciences Inc |
RSLS |
10% Owner |
2021-06-28 |
7,223,346 |
2021-06-28 |
7,223,346 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
790 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 31 of 32
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
RSLS |
ReShape Lifesciences Inc |
10% Owner |
|
2021-06-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
0 |
7,223,346 |
0 |
- |
|
RSLS |
ReShape Lifesciences Inc |
10% Owner |
|
2021-06-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,130,806 |
7,223,346 |
0 |
- |
|
KPRX |
Kiora Pharmaceuticals |
Director |
|
2021-07-27 |
4 |
OE |
$4.80 |
$4,092,000 |
I/I |
852,500 |
4,199,101 |
0 |
- |
|
KPRX |
Kiora Pharmaceuticals |
Director |
|
2021-07-27 |
4 |
S |
$3.80 |
$12,113,647 |
I/I |
(2,377,695) |
1,821,406 |
0 |
- |
|
KPRX |
Kiora Pharmaceuticals |
Director |
|
2021-07-28 |
4 |
S |
$3.28 |
$1,232,617 |
I/I |
(375,443) |
1,445,963 |
0 |
- |
|
KPRX |
Kiora Pharmaceuticals |
Director |
|
2021-07-29 |
4 |
S |
$3.00 |
$1,200,000 |
I/I |
(400,000) |
1,045,963 |
0 |
- |
|
KPRX |
Kiora Pharmaceuticals |
10% Owner |
|
2021-07-30 |
4 |
S |
$2.69 |
$183,562 |
I/I |
(68,188) |
977,775 |
0 |
- |
|
KPRX |
Kiora Pharmaceuticals |
10% Owner |
|
2021-08-02 |
4 |
S |
$2.40 |
$463,046 |
I/I |
(192,775) |
785,000 |
0 |
- |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2021-08-04 |
4 |
B |
$2.69 |
$268,590 |
I/I |
100,000 |
39,200,000 |
1.5 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2021-08-05 |
4 |
B |
$2.77 |
$69,295 |
I/I |
25,000 |
39,225,000 |
1.5 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
10% Owner |
|
2021-08-06 |
4 |
B |
$2.83 |
$70,630 |
I/I |
25,000 |
39,250,000 |
1.5 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2021-08-16 |
4 |
B |
$2.75 |
$82,638 |
I/I |
30,000 |
39,280,000 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2021-08-18 |
4 |
B |
$2.78 |
$55,550 |
I/I |
20,000 |
39,300,000 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2021-09-15 |
4 |
B |
$2.26 |
$215,948 |
I/I |
95,455 |
39,395,455 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2021-09-16 |
4 |
B |
$2.28 |
$341,955 |
I/I |
150,000 |
39,545,455 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2021-09-17 |
4 |
B |
$2.20 |
$11,999,999 |
I/I |
5,454,545 |
45,000,000 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-07 |
4 |
B |
$1.04 |
$142,975 |
I/I |
137,900 |
45,137,900 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-10 |
4 |
B |
$0.99 |
$484,615 |
I/I |
491,097 |
45,628,997 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-11 |
4 |
B |
$0.96 |
$15,342 |
I/I |
16,003 |
45,645,000 |
2.17 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-12 |
4 |
B |
$1.04 |
$59,781 |
I/I |
57,300 |
45,702,300 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-13 |
4 |
B |
$1.00 |
$314,013 |
I/I |
312,700 |
46,015,000 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-14 |
4 |
B |
$0.93 |
$78,974 |
I/I |
85,000 |
46,100,000 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-18 |
4 |
B |
$0.88 |
$182,225 |
I/I |
206,300 |
46,306,300 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-19 |
4 |
B |
$0.88 |
$82,053 |
I/I |
93,700 |
46,400,000 |
2.25 |
% |
|
AVTX |
Avalo Therapeutics, Inc |
Director |
|
2022-01-20 |
4 |
B |
$0.85 |
$10,208 |
I/I |
12,000 |
46,412,000 |
2.17 |
% |
|
790 Records found
|
|
Page 31 of 32 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|